Pauline T. Merrill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pauline T. Merrill has a total of 655 co-authors. Here are the top co-authors by number of shared publications:
Debra A. Goldstein
4 shared publicationsGlenn J. Jaffe
Department of Ophthalmology, Duke University, Durham, North Carolina
4 shared publications- Lyndell Lp Lim
Centre for Eye Research Australia Royal Victorian Eye and Ear Hospital Melbourne Victoria Australia
4 shared publications - Quan Dong Nguyen
Byers Eye Institute, Stanford University School of Medicine, Palo Alto, USA
4 shared publications Albert T. Vitale
Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, Utah
3 shared publicationsAlyce Burke
Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD
3 shared publications
Latest Publications
- Open Access
- 25 January 2024
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 44 (4) , 545-551
Optic Disc Edema Is an Under-Recognized Feature of Birdshot Chorioretinitis
Background: Optic disc edema is a feature of many ophthalmic and neurologic conditions. It remains an underappreciated feature of birdshot chorioretinitis (BSCR), leading to delay in diagnosis and treatment. The purpose of our study was to identify clinical features that are concomitant with optic disc edema and suggest a diagnosis of BSCR. Methods: Retrospective multicenter case series of 29 patients who were referred to a neuro-ophthalmologist or uveitis specialist for evaluation of disc edema and were ultimately diagnosed with BSCR. Results: Fifty-four eyes of 30 patients, from the practices of 15 uveitis specialists, met the eligibility criteria. In addition to disc edema, concomitant features in all patients included vitritis, chorioretinal lesions, and retinal vasculitis. Visual recovery to 20/40 or better occurred in 26 of 29 patients. Visual acuity remained 20/100 or worse in 2 patients previously diagnosed with idiopathic intracranial hypertension, 1 patient previously diagnosed with optic neuritis, and 1 patient for whom treatment was delayed for years, leading to optic disc atrophy. Conclusions: Optic disc edema is a presenting feature in some cases of BSCR. A diagnosis of BSCR should be considered when disc edema occurs with vitritis, chorioretinal inflammation, and retinal vasculitis. Patients should be referred to a uveitis specialist for treatment.
- 25 January 2024
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 44 (4) , 545-551
Open AccessOptic Disc Edema Is an Under-Recognized Feature of Birdshot Chorioretinitis
Background: Optic disc edema is a feature of many ophthalmic and neurologic conditions. It remains an underappreciated feature of birdshot chorioretinitis (BSCR), leading to delay in diagnosis and treatment. The purpose of our study was to identify clinical features that are concomitant with optic disc edema and suggest a diagnosis of BSCR. Methods: Retrospective multicenter case series of 29 patients who were referred to a neuro-ophthalmologist or uveitis specialist for evaluation of disc edema and were ultimately diagnosed with BSCR. Results: Fifty-four eyes of 30 patients, from the practices of 15 uveitis specialists, met the eligibility criteria. In addition to disc edema, concomitant features in all patients included vitritis, chorioretinal lesions, and retinal vasculitis. Visual recovery to 20/40 or better occurred in 26 of 29 patients. Visual acuity remained 20/100 or worse in 2 patients previously diagnosed with idiopathic intracranial hypertension, 1 patient previously diagnosed with optic neuritis, and 1 patient for whom treatment was delayed for years, leading to optic disc atrophy. Conclusions: Optic disc edema is a presenting feature in some cases of BSCR. A diagnosis of BSCR should be considered when disc edema occurs with vitritis, chorioretinal inflammation, and retinal vasculitis. Patients should be referred to a uveitis specialist for treatment.
- Open Access
- 22 May 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 252, 336
Corrigendum to “The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema” [Am J Ophthalmol 2023;248;16-23]
- 22 May 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 252, 336
Open AccessCorrigendum to “The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema” [Am J Ophthalmol 2023;248;16-23]
- Open Access
- 9 October 2022
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 248, 16-23
The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema
- 9 October 2022
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 248, 16-23
Open AccessThe 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema
- Open Access
- 18 August 2021
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 31 (8) , 1579-1586
Suprachoroidal CLS-TA with and without Systemic Corticosteroid and/or Steroid-Sparing Therapy: A Post-Hoc Analysis of the Phase 3 PEACHTREE Clinical Trial
To study the efficacy and safety of suprachoroidal CLS-TA (proprietary suspension of triamcinolone acetonide) in uveitic macular edema (UME) with and without concurrent systemic corticosteroid or s...
- 18 August 2021
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 31 (8) , 1579-1586
Open AccessSuprachoroidal CLS-TA with and without Systemic Corticosteroid and/or Steroid-Sparing Therapy: A Post-Hoc Analysis of the Phase 3 PEACHTREE Clinical Trial
To study the efficacy and safety of suprachoroidal CLS-TA (proprietary suspension of triamcinolone acetonide) in uveitic macular edema (UME) with and without concurrent systemic corticosteroid or s...
- Open Access
- 1 June 2021
- Published by Elsevier in Ophthalmology
- Vol. 128 (6) , 899-909
Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
- 1 June 2021
- Published by Elsevier in Ophthalmology
- Vol. 128 (6) , 899-909
Open AccessLong-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
- 21 May 2021
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 6 (5) , 409-411
Unilateral Retinal Vasculitis as the Presenting Manifestation of Parry-Romberg Syndrome (Progressive Hemifacial Atrophy)
Purpose: This work aims to present a case of retinal vasculitis associated with Parry-Romberg syndrome. Method: A case report is presented. Results: A 17-year-old man with new floaters was found to have 20/40 vision with 1+ vitreous cell and retinal vasculitis in the right eye only. Workup for infectious etiologies did not reveal an explanation for the retinal vasculitis. However, magnetic resonance imaging of the head showed areas of linear band-like atrophy and scarring of the scalp and soft tissues as well as areas of gliosis and encephalomalacia in the subcortical white matter, all of which were consistent with Parry-Romberg syndrome. The patient was prescribed oral steroids and methotrexate, and the retinal vasculitis improved. Conclusions: Parry-Romberg syndrome is a rarely reported cause of retinal vasculitis and should be kept in the differential for retinal vasculitis.
- 21 May 2021
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 6 (5) , 409-411
Unilateral Retinal Vasculitis as the Presenting Manifestation of Parry-Romberg Syndrome (Progressive Hemifacial Atrophy)
Purpose: This work aims to present a case of retinal vasculitis associated with Parry-Romberg syndrome. Method: A case report is presented. Results: A 17-year-old man with new floaters was found to have 20/40 vision with 1+ vitreous cell and retinal vasculitis in the right eye only. Workup for infectious etiologies did not reveal an explanation for the retinal vasculitis. However, magnetic resonance imaging of the head showed areas of linear band-like atrophy and scarring of the scalp and soft tissues as well as areas of gliosis and encephalomalacia in the subcortical white matter, all of which were consistent with Parry-Romberg syndrome. The patient was prescribed oral steroids and methotrexate, and the retinal vasculitis improved. Conclusions: Parry-Romberg syndrome is a rarely reported cause of retinal vasculitis and should be kept in the differential for retinal vasculitis.
- Open Access
- 12 March 2021
- Published by BMJ in British Journal of Ophthalmology
- Vol. 106 (8) , 1139-1144
Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA)
Purpose To assess the extended efficacy and safety of suprachoroidal triamcinolone acetonide injectable suspension (CLS-TA) among patients with macular oedema (ME) secondary to non-infectious uveitis (NIU). Methods Patients with uveitic ME were treated with suprachoroidal CLS-TA at baseline and week 12 of the Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial (PEACHTREE) study. Time to rescue was evaluated over 24 additional weeks for MAGNOLIA. Safety data, visual acuity and retinal central subfield thickness (CST) reduction were also evaluated. Of the 53 eligible patients (46 CLS-TA and 7 control), 33 patients were enrolled (28 CLS-TA and 5 control). Results Over the entire 48-week period for PEACHTREE and MAGNOLIA, the median time to rescue therapy was 257 days versus 55.5 days for the CLS-TA and sham-control arms, respectively. Of 28 CLS-TA treated patients who participated in MAGNOLIA, 14 (50%) did not require rescue therapy through approximately 9 months after the second treatment. Among CLS-TA patients not requiring rescue, there was a mean gain of 12.1 letters and mean CST reduction of 174.5 µm at week 48. No serious adverse events related to study treatment were observed. Conclusion Approximately 50% of patients did not require additional treatment for up to 9 months following the last CLS-TA administration.
- 12 March 2021
- Published by BMJ in British Journal of Ophthalmology
- Vol. 106 (8) , 1139-1144
Open AccessExtension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA)
Purpose To assess the extended efficacy and safety of suprachoroidal triamcinolone acetonide injectable suspension (CLS-TA) among patients with macular oedema (ME) secondary to non-infectious uveitis (NIU). Methods Patients with uveitic ME were treated with suprachoroidal CLS-TA at baseline and week 12 of the Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial (PEACHTREE) study. Time to rescue was evaluated over 24 additional weeks for MAGNOLIA. Safety data, visual acuity and retinal central subfield thickness (CST) reduction were also evaluated. Of the 53 eligible patients (46 CLS-TA and 7 control), 33 patients were enrolled (28 CLS-TA and 5 control). Results Over the entire 48-week period for PEACHTREE and MAGNOLIA, the median time to rescue therapy was 257 days versus 55.5 days for the CLS-TA and sham-control arms, respectively. Of 28 CLS-TA treated patients who participated in MAGNOLIA, 14 (50%) did not require rescue therapy through approximately 9 months after the second treatment. Among CLS-TA patients not requiring rescue, there was a mean gain of 12.1 letters and mean CST reduction of 174.5 µm at week 48. No serious adverse events related to study treatment were observed. Conclusion Approximately 50% of patients did not require additional treatment for up to 9 months following the last CLS-TA administration.
- 7 June 2019
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 3 (4) , 242-245
Undiagnosed Ocular Syphilis Treated With Immunosuppressive Therapy
Purpose: The purpose of this case series is to illustrate the importance of diagnosis and treatment of infectious uveitis and to suggest syphilis screening guidelines before the initiation of immunosuppressive therapy. Method: A retrospective case series (2016-2018) from a Chicago-area academic retina practice was conducted. Primary outcomes include ocular syphilis response to discontinuation of immunomodulatory agents and initiation of penicillin treatment as assessed by improvement of visual acuity and ocular inflammation. Results: Three patients with ocular syphilis in the setting of immunosuppressive therapy are presented. Two cases were identified of misdiagnosed ocular syphilis in patients initially treated with immunosuppressive therapy including adalimumab for their uveitis. A third case of ocular syphilis in a patient being treated with infliximab for ankylosing spondylitis is also presented. Once laboratory testing confirmed the presence of syphilis, immunosuppressive therapies were immediately stopped; signs of inflammation and visual acuity improved with adequate treatment for neurosyphilis including intravenous penicillin. Conclusions: Ocular syphilis may present in a variety of ways and cannot be ruled out without appropriate testing. Syphilitic uveitis should be on the differential of any patient presenting with ocular inflammation and screened for accordingly. It is particularly critical that syphilis be screened for before starting immunosuppressive treatment for uveitis to minimize the risk of long-term ocular damage from a treatable infectious uveitis. These cases convey the importance of establishing guidelines around screening for syphilis prior to starting immunosuppressive treatment for uveitis.
- 7 June 2019
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 3 (4) , 242-245
Undiagnosed Ocular Syphilis Treated With Immunosuppressive Therapy
Purpose: The purpose of this case series is to illustrate the importance of diagnosis and treatment of infectious uveitis and to suggest syphilis screening guidelines before the initiation of immunosuppressive therapy. Method: A retrospective case series (2016-2018) from a Chicago-area academic retina practice was conducted. Primary outcomes include ocular syphilis response to discontinuation of immunomodulatory agents and initiation of penicillin treatment as assessed by improvement of visual acuity and ocular inflammation. Results: Three patients with ocular syphilis in the setting of immunosuppressive therapy are presented. Two cases were identified of misdiagnosed ocular syphilis in patients initially treated with immunosuppressive therapy including adalimumab for their uveitis. A third case of ocular syphilis in a patient being treated with infliximab for ankylosing spondylitis is also presented. Once laboratory testing confirmed the presence of syphilis, immunosuppressive therapies were immediately stopped; signs of inflammation and visual acuity improved with adequate treatment for neurosyphilis including intravenous penicillin. Conclusions: Ocular syphilis may present in a variety of ways and cannot be ruled out without appropriate testing. Syphilitic uveitis should be on the differential of any patient presenting with ocular inflammation and screened for accordingly. It is particularly critical that syphilis be screened for before starting immunosuppressive treatment for uveitis to minimize the risk of long-term ocular damage from a treatable infectious uveitis. These cases convey the importance of establishing guidelines around screening for syphilis prior to starting immunosuppressive treatment for uveitis.
- Open Access
- 1 December 2018
- Published by Elsevier in Ophthalmology
- Vol. 125 (12) , 1984-1993
Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis
- 1 December 2018
- Published by Elsevier in Ophthalmology
- Vol. 125 (12) , 1984-1993
Open AccessIntravitreal Sirolimus for the Treatment of Noninfectious Uveitis
- 23 November 2016
- Published by Springer Nature
- p. 149-162
Surgical Management of Macular Edema Associated with Uveitis
- 23 November 2016
- Published by Springer Nature
- p. 149-162
Surgical Management of Macular Edema Associated with Uveitis